LMRA was up 3.14% & continued to add another 4.16% AHs, apparently in response to its announcement yesterday that Plexera had signed an agreement with a "therapeutic antibody company" that will participate in its "Early Access Program".<g>
bigcharts.marketwatch.com
Plexera Bioscience Announces Agreement with Leading Therapeutic Antibody Company
Tuesday November 13, 8:45 am ET
BOTHELL, Wash.--(BUSINESS WIRE)--Plexera Biosciences LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA - News), announced today that it has signed an Early Access Agreement with an undisclosed leading therapeutic antibody company as its first participant in the company’s Early Access Program.
As part of the Early Access Program, prospective customers will evaluate the performance of the Plexera antibody discovery system over a defined period of time, provide detailed user feedback, and intend to purchase a system upon product launch. A commercial version of the product is expected to be launched in May 2008 at PEGS: “The Protein Engineering Summit.”
“The Early Access Program and in particular this initial agreement with a world leader in the field of recombinant antibodies are important steps in our development and commercialization plan,” said Dr. Tim Londergan, Plexera’s President and Chief Operating Officer.
“It takes us one step further towards full commercialization. The past 18 months have been invested gathering customer feedback on the system which has received strong support from esteemed academic institutions. We have now enabled a viable evaluation program to address the pharmaceutical industry and facilitate future commercial agreements.”
The ProteomicProcessorTM System offers antibody researchers the opportunity to greatly increase the efficiency of their discovery processes. By combining the analytical advantages of Surface Plasmon Resonance (SPR) with the multiplex capabilities of microarrays, the ProteomicProcessorTM System provides label-free, real-time detection and monitoring of biomolecular binding kinetics for up to 5,000 antigen-antibody interactions in a single run.
Current methodologies to screen potentially therapeutic antibodies are multi-stepped and often slow and cumbersome. Researchers frequently use enzyme-linked immunosorbent assays (ELISA) to screen for specific antibodies of interest. Next, the resultant candidates are evaluated for their binding properties, concentration, and kinetics using low-throughput monitoring tools.
By combining these steps into one high-throughput process, it is envisioned that Plexera’s ProteomicProcessor™ System will significantly accelerate the drug discovery process.
Snip
LMRA needs to close above $4 before it can test the heavier resistance at the $4.70 level.<g>
bigcharts.marketwatch.com
But with some good news the stock can move fast as it did around this time last Yr.<g>
bigcharts.marketwatch.com
Bernard |
